Effects of AMPA receptor antagonists on dopamine-mediated behaviors in mice

Psychopharmacology

Volumn 136, Issue 2, 1998, Pages 123-131

  Vanover, Kimberly E ^a  

^a Department of Pharmacokinetics and Drug Metabolism   (United States)

Author keywords

AMPA; Antipsychotic; Behavior; Climbing; Dopamine; Glutamate; Kainate; Locom otion; Mouse; Schizophrenia; Stereotypy

Indexed keywords

1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; AMPA RECEPTOR ANTAGONIST; DECAHYDRO 6 [2 (1H TETRAZOL 5 YL)ETHYL] 3 ISOQUINOLINECARBOXYLIC ACID; TALAMPANEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CLIMBING; DOPAMINE BRAIN LEVEL; DRUG EFFECT; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; STEREOTYPY;

ANIMALS; ANTI-ANXIETY AGENTS; BENZODIAZEPINES; DOPAMINE; EXCITATORY AMINO ACID ANTAGONISTS; ISOQUINOLINES; MALE; MICE; MOTOR ACTIVITY; QUINOXALINES; RECEPTORS, AMPA; STEREOTYPED BEHAVIOR; TETRAZOLES;

EID: 0031907589     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050547     Document Type: Article

References (35)

1. Arnt J (1995) Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine. Eur J Pharmacol 283:55-62
2. Benvenga MJ, Ornstein PL, Leander JD (1995) Schedule-controlled behavioral effects of the selective 2-amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)propanoic acid antagonist LY293558 in pigeons. J Pharmacol Exp Ther 275:164-170
3. Boulter J, Hollmann M, O'Shea-Greenfield A, Hartley M, Deneris E, Maron C, Heinnemann S (1990) Molecular cloning and functional expression of glutamate receptor subunit genes. Science 249:1033-1037
4. Bubser M, Tzschentke T, Hauber W (1995) Behavioural and neurochemical interactions of the AMPA antagonist GYKI 52466 and the non-competitive NMDA antagonist dizocilpine in rats. J Neural Transm [Gen Sec] 101:115-126
5. Burns LH, Sato K, Wullner U, Isacson O (1993) Intra-nigra infusion of AMPA attenuates dopamine-dependent rotation in the rat. Neuroreport 4:1075-1078
6. Burns LH, Everitt BJ, Kelley AE, Robbins TW (1994) Glutamate-dopamine interactions in the ventral striatum: role in locomotor activity and responding with conditioned reinforcement. Psychopharmacology 115:516-528
7. Carboni E, Imperato A, Perezzani L, Di Chiara G (1989) Amphetamine, cocaine, phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in the nucleus accumbens of freely moving rats. Neuroscience 28:653-661
8. Corbett R, Camacho F, Woods AT, Kerman LL, Fishkin RJ, Brooks K, Dunn RW (1995) Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology 120:67-74
9. Donevan SD, Rogawski MA (1993) GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses. Neuron 10:51-59
10. Hauber W, Andersen R (1993) The non-NMDA glutamate receptor antagonist GYKI 52466 counteracts locomotor stimulation and anticataleptic activity induced by the NMDA antagonist dizocilpine. Naunyn-Schmiedeberg's Arch Pharmacol 348: 486-490
11. Hauber W, Walenmeier MT (1994) The AMPA receptor antagonist GYKI 52466 reverses the anti-cataleptic effects of the competitive NMDA receptor antagonist CGP 37849. Eur J Pharmacol 256:339-342
12. Hoffman DC (1992) Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats. J Neural Transm [GenSect] 89:1-10
13. Jedema HP, Moghaddam B (1996) Characterization of excitatory amino acid modulation of dopamine release in the prefrontal cortex of conscious rats. J Neurochem 66:1448-1453
14. Karcz-Kubicha M, Liljequist S (1995) Evidence for an anxiogenic action of AMPA receptor antagonists in the plus-maze test. Eur J Pharmacol 279:171-177
15. Karreman M, Westerink BH, Moghaddam B (1996) Excitatory amino acid receptors in the ventral tegmental area regulate dopamine release in the ventral striatum. J Neurochem 67:601-607
16. Kuczenski R, Segal D (1989) Concomitant characterization of behavioral and striatal neurotransmitter response to amphetamine using in vivo microdialysis. J Neurosci 9:2051-2065
17. 2+ responses and neurotoxicity in rat cortical and cerebellar granule neurons. Biochem Pharmacol 50:1761-1774
18. Ljungberg T, Ungerstedt U (1985) A rapid and simple behavioural screening method for simultaneous assessment of limbic and striatal blocking effects of neuroleptic drugs. Pharmacol Biochem Behav 23:479-485
19. Maj J, Rogoz Z, Skuza G, Jaros T (1995a) Some behavioral effects of CNQX and NBQX, AMPA receptor antagonist. Pol J Pharmacol 47:269-277
20. Maj J, Rogoz Z, Skuza G, Kolodziejczyk K (1995b) Some central effects of GYKI 52466, a non-competitive AMPA receptor antagonist. Pol J Pharmacol 47:501-507
21. Moghaddam B, Roth RH, Bunney BS (1990) Characterization of dopamine release in the rat medial prefrontal cortex as assessed by in vivo microdialysis: comparison to the striatum. Neuroscience 36:669-676
22. Ornstein PL, Arnold MB, Augenstein NK, Lodge D, Leander JD, Schoepp DD (1993) (3SR, 4aRS, 6RS, 8aRS)-6-[2-(II-1-Tetrazol-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid: a structurally novel, systemically active, competitive AMPA receptor antagonist. J Med Chem 36:2046-2048
23. Rao TS, Kim HS, Lehmann J, Martin LL, Wood PL (1989) Differential effects of phencyclidine (PCP) and ketamine on mesocortical and mesostriatal dopamine release in vivo. Life Sci 45:1065-1072
24. 2A receptor blockade. J Pharmacol Exp Ther 277:1541-1549
25. Schoepp DD, Lodge D, Bleakman D, Leander JD, Tizzano JP, Wright RA, Palmer AJ, Salhoff CR, Ornstein PL (1995) In vitro and in vivo antagonism of AMPA receptor activation by (3S, 4aR, 6R, 8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid. Neuropharmacology 34:1159-1168
26. Sheardown MJ, Nielsen EO, Hansen AJ, Jacobsen P, Honore T (1990) 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia. Science 247: 571-574
27. Vizi ES, Mike A, Tarnawa I (1996) 2,3-Benzodiazepines (GYKI 52466 and analogs): negative allosteric modulators of AMPA receptors. CNS Drug Rev 2:91-126
28. Wan FJ, Geyer MA, Swerdlow NR (1995) Presynaptic dopamine-glutamate interactions in the nucleus accumbens regulate sensorimotor gating. Psychopharmacology 120:433-441
29. 1 receptors. Brain Res 622:325-329
30. Westerink BHC, Kwint H-F, deVries JB (1996) The pharmacology of mesolimbic dopamine neurons: a dual probe microdialysis study in the ventral tegmental area and nucleus accumbens of the rat brain. J Neurosci 16:2605-2611
31. Willins DL, Wallace LJ, Miller DD, Uretsky NJ (1992) α-Amino-3-hydroxy-5-methylisoxazole-4-proprionate/kainate receptor antagonists in the nucleus accumbens and ventral pallidum decrease the hypermotility response to psychomotor stimulant drugs. J Pharmacol Exp Ther 260:1145-1151
32. Willins DL, Narayanan S, Wallace LJ, Uretsky NJ (1993) The role of dopamine and AMPA/Kainate receptors in the nucleus accumbens in the hypermotility response to MK801. Pharmacol Biochem Behav 46:881-887
33. Witkin JM (1993) Blockade of the locomotor stimulant effects of cocaine and methamphetamine by glutamate antagonists. Life Sci 53:PL405-410
34. Worms P, Broekkammp CLE, Lloyd KG (1983) Behavioral effects of neuroleptics. In: Coyle JT, Enna SJ (eds) Neuroleptics: neurochemical behavioral, and clinical perspectives. Raven Press, New York, pp 93-117
35. Zetterstrom T, Sharp T, Marsden CA, Ungerstedt U (1993) In vivo measurement of dopamine and its metabolites by intracerebral dialysis: changes after d-amphetamine. J Neurochem 41:1769-1773